MedPath

Study of zonisamide ( TRERIEF® tablet 25mg ) to tremor in patients with early Parkinson's disease.

Not Applicable
Conditions
Parkinson&#39
s disease
Registration Number
JPRN-UMIN000010371
Lead Sponsor
Department of Neurology, University of Yamanashi
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
10
Inclusion Criteria

Not provided

Exclusion Criteria

1) Patients with Parkinsonism other than Parkinson's disease 2) Patients who have taken zonisamide 3) Patients with dementia : [Mini Mental State Examination (MMSE) score is less than 22points 4) Patients with severs disease of heart, renal, liver, and other life-threatening diseases 5) Patients who are determined as unfit for the study by attending physicians for reasons other than those stated above

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The change of tremor detected by actigraph
Secondary Outcome Measures
NameTimeMethod
The change of UPDRS Part 2,3 The change of RBDSQ-J Adverse Events
© Copyright 2025. All Rights Reserved by MedPath